Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance

Drug Saf. 2020 Nov;43(11):1191-1194. doi: 10.1007/s40264-020-00990-9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adverse Drug Reaction Reporting Systems
  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use*
  • Female
  • Global Health
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / mortality
  • Lung Diseases, Interstitial / pathology
  • Male
  • Pharmacovigilance*
  • United States
  • United States Food and Drug Administration

Substances

  • Anticoagulants